TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency
What is the purpose of this trial?
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.
- Ages18 years and older
- GenderMale only
- Trial withClovis Oncology, Inc.
- Start Date06/04/2018
- End Date02/27/2022
- Last Updated12/05/2018
- Study HIC#2000020657